

Robert C. Welliver Sr, M.D.

Professor of Pediatrics
Children's Hospital Foundation Hobbs-Recknagel Endowed Chair in Pediatrics
Chief, Division of Pediatric Infectious Diseases
Children's Hospital at University of Oklahoma Health Sciences Center
Department of Pediatrics
College of Medicine
University of Oklahoma Health Sciences Center

Contact Information:

E-mail: robert-welliver@ouhsc.edu
Office: 1200 Children's Avenue, Suite 12112, Oklahoma City, OK 73104
Phone 405-271-5703
Fax 405-271-2281

Education:

1968: BS, Psychology, University of Florida
1972: MD, Medicine, University of Florida College of Medicine

Academic Appointments:

1975-1977: Infectious Disease Fellow, Department of Pediatrics, UCLA Hospital, Los Angeles
1977-1978: Research Assistant Professor, Department of Pediatrics, Division of Infectious Diseases, Children's Hospital, SUNYAB, Buffalo
1978-1982: Asst. Professor, Dept. of Peds., Division of Infectious Diseases, Children's Hospital, SUNYAB
1982-1987: Assoc. Professor, Dept. of Peds., Division of Infectious Diseases, Children's Hospital, SUNYAB
1987- 2010: Professor, Dept. of Peds., Division of Infectious Diseases, Children's Hospital, SUNYAB
2010: Co-Director, Division of Infectious Diseases, Children's Hospital, SUNYAB
2011-present: Professor, Dept. of Pediatrics, Oklahoma University Health Science Center
2011-present: Chief, Section of Infectious Diseases, OUHSC

Awards and Honors:

2017-2018: Outstanding Faculty Award
2017-2018: Medical Education Committee, OU College of Medicine
2017-2018: Outstanding Subspecialty Faculty Teaching Award, Pediatric Residents, OUHSC
2014-2015: Outstanding Faculty Teaching Award, Pediatric Residents, OUHSC
2017: "Top Doctors" in Oklahoma City, 405 Magazine
2014-2015: Outstanding Faculty Teaching Award, Pediatric Residents, OUHSC
2015: Cited by the OUHSC pediatric residents as one of five faculty members best exemplifying Humanism in Medicine:
2015-2016: "Top Doctors", Oklahoma magazine
2004-2005: Consumer's Research Council of America "Guide to America's Top Pediatricians"
1979: Wilkes Award: Outstanding Teacher (for Residents)
1994: Siegal Award for Excellence in Teaching (for students), SUNYAB

Research Support:

Current:

- 2019-2020: NIAID 1 R41 A147787-01, "Development of an M Protein-Deficient Respiratory Syncytial Virus Vaccine for Aerosolized Vaccination of the Lung", Role: Principal Investigator, Awarded: \$267,672
- 2018-2022: NIH/NIBIB 1 R01 EB 025596-01, Role: Consultant, Awarded: \$66,664
- 2018-2023: NIH-NIGMS 1P20GM103648, Role: Consultant, Awarded: \$106,690

Past:

- 2013-2018: Oklahoma Center for Respiratory and Infectious Disease (PI: Lin Liu), Role: Co-Investigator, Awarded: \$31,159 annually
- 2017-2018: "A Phase 2b Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants", Medimmune LLC, Role: Site PI, Awarded: \$30,000
- 2015-2016: The SENTINEL 1, "Study: An Observational, Non-Interventional Study in the United States to Characterize Respiratory Syncytial Virus Hospitalizations among Infants Born at 29 to 35 Weeks Gestational Age Not Receiving Immunoprophylaxis, Astra-Zeneca," Role: Principal Investigator (site), Awarded: \$29,650.50
- 2015: Novavax Ebola Virus Vaccine Immunogenicity Study, Novavax, Role: Principle Investigator, Awarded: \$39,208.16
- 2015: Novavax Ebola Vaccine Immunogenicity Study, Novavax, Role: Principle Investigator, Awarded: \$276,405.48
- 2014-2015: The SENTINEL 1 Study: An Observational, Non-Interventional Study in the United States to Characterize Respiratory Syncytial Virus Hospitalizations among Infants Born at 29 to 35 Weeks Gestational Age Not Receiving Immunoprophylaxis, Astra-Zeneca, Role: Principle Investigator, Awarded: \$28,850
- 2014: Novavax Ebola Virus Vaccine Immunogenicity Study, Novavax, Role: Principle Investigator, Awarded: \$130,204.52
- 2010-2011: Akebia, Inc., "The Effect of AKB-9778 on the Outcome of Influenza Virus Infection in a Mouse Model.", Role: PI
- 2010–2011: Akebia, Inc, "AKB-4924 in Respiratory Syncytial Virus Infection in Mice.", Role: PI
- 2009–2011: MedImmune, "Effect of isoflurane anesthesia on inflammatory response to Respiratory Syncytial Virus infection.", Role: PI
- 2009–2011: MedImmune, "An Observational Prospective Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants (32 to 35 Week Gestational Age) - Outcomes and Risk Tracking Study (The Report Study).", Role: Site PI
- 2009–2010: (Grant), "Randomized, controlled trial of live attenuated influenza vaccine in extremely premature infants."
- 2009–2010: (Grant), "Anti-RSV antibodies in the NZB RSV challenge model.", Role: PI

Selected Publications:

1. Ivanov V, Wolf RF, Papin JF, Hill C, Anderson M, Welliver RC Sr. Apnea induction for invasive lung function testing in infant olive baboons: Comparison of intravenous propofol versus hyperventilation. *J Med Primatol* (in press, 2017).
2. Hughes KM, Johnson PN, Anderson MP, Sekar KC, Welliver RC Sr., Miller JL. Comparison of amikacin pharmacokinetics in neonates pre- and post- a dosing protocol change. *J Pediatr Pharmacol Ther* 2017;22(1):33–40 DOI: 10.583/1551-6776-22.1.33.
3. Anderson EJ, Krilov LR, DeVincenzo JP, Checchia PA, Halasa N, Simões EAF, Domachowske JB, Forbes ML,, Pannaraj PS, McBride SJ, McLaurin KK, Kumar VR, Ambrose CS. And others including Welliver RC Sr. SENTINEL 1: An observational study of respiratory syncytial virus hospitalizations among United States Infants born at 29-35 weeks' gestational age not receiving immunoprophylaxis. *Amer J Perinatol* published online May 2016 DOI <http://dx.doi.org/10.1055/3-0036-1584147>. ISSN 0735-1631.
4. Welliver RC Sr.: Bronchiolitis and Infectious Asthma. In Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 8th edition. Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ and Hotez PJ, Eds. Elsevier, Philadelphia PA, (in press, 2017).
5. Welliver RC Sr., Meissner HC and Hall CB: Respiratory syncytial virus. In Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 8th edition. Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ and Hotez PJ, Eds. Elsevier, Philadelphia PA, (in press, 2017).

6. Welliver RC Sr and Hall CB. Parainfluenza Viruses. In Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 8th edition. Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ and Hotez PJ, Eds. Elsevier, Philadelphia PA, (in press, 2017).
7. Simoes EAF, Carbonell-Estrany X, Guilbert T, Mansbach JM, Piedra PA, Ramilo O, Welliver RC Sr. Clinical endpoints for RSV prophylaxis trials in infants and children in industrialized countries. *The Pediatric Infectious Disease Journal* 06/2015; DOI:10.1097/INF.0000000000000813 PMID 26121204.
8. Papin JF, Wolf RF, Kosanke SD, Jenkins JD, Moore SN, Anderson MP, Welliver RC Sr. Infant Baboons Infected with Respiratory Syncytial Virus Develop Clinical and Pathologic Changes that Parallel Those of Human Infants. *Amer J Physiol Lung Cell Mol Physiol* 2013 April15;304(8):L530-9. doi:10.1153/ajplung.00173.2012.
9. D'Angio CT, Heyne RJ, Duara S, Holmes LC, O'Shea TM, Wang H, Wang D, Sanchez PJ, Welliver RC Sr., Ryan RM, Schnabel KC, Hall CB. Immunogenicity of Trivalent Influenza Vaccine in Extremely-Low-Birth-Weight, Premature versus Term Infants. *Pediatr Infect Dis J* (in press, 2011).
10. Abarca K, Jung E, Fernandez P, Zhao L, Harris B, Connor E, Losonsky G for the Motavizumab Study Group: Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk Children. *Pediatr Infect Dis J* 2009;28: 267–272.
11. Elliott MB, Welliver RC Sr, Laughlin TS, Pryharski KS, Lapierre NA, Chen T, Souza V, Terio NB, and Hancock GE: Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in the respiratory tracts of human infants following paramyxovirus infection. *J. Med. Virol.* 79:447-456, 2007.
12. Ivanov V, Wolf RF, Papin JF, Hill C, Anderson M, Welliver RC Sr. Apnea induction for invasive lung function testing in infant olive baboons: Comparison of intravenous propofol versus hyperventilation. *J Med Pr* 2017 Oct 12. doi: 10.1111/jmp.12306. PMID 29023804.
13. Andersson C, Shikhagaie M, Mori M, Al-Garawi A, Reed J, Humbles A, **Welliver RC Sr**, Mauad T, Bjermer L, Jordana M, Erjefalt J. Distal Respiratory Tract Viral Infections in Young Children Trigger a Marked Increase in Alveolar Mast Cells. *Eur Resp J Open Research.* 2018; 4:00038-2018. doi.org/10.1183/2310541.00038-2018.
14. Miller J, Johnson P, White B, Neely S, Chaaban H, Kassa N, **Welliver RC Sr**, Impact of Ceftazidime Use on Susceptibility Patterns in the Neonatal Intensive Care Unit, *The Pediatric Infectious Disease Journal*: [2019;38:605-607](https://doi.org/10.1097/INF.0000000000002255) doi: 10.1097/INF.0000000000002255.
15. Anderson EJ, DeVincenzo JP, Simoes EAF, Krilov LR, Forbes ML, Pannaraj PS, Epsinosa CM, **Welliver RC Sr**, Wolkoff LI, Yogev R, Checchia PA, Domachowske JB, Halasa N, McBride SJ, Kumar VR, McLaurin KK, Rizzo CP, Ambrose CS. Sentinel 1. Two-season study of respiratory syncytial virus hospitalizations among US infants born at 29 to 35 weeks gestational age not receiving immunoprophylaxis. *Amer J Perinatol*, (In press, 2019).